Clinical application of human papillomavirus E6/E7 mRNA determination

doi:10.3969/j.issn.1673-8640.2018.07.015

Abstract

Abstract:

Objective To evaluate the applicability of human papillomavirus（HPV） E6/E7 mRNA determination for screening HPV infection. Methods A total of 5 308 women were enrolled. Thinprep cytologic test（TCT）was performed. HPV DNA determination was performed in 4 062 cases,and HPV E6/E7 mRNA determination was performed in 1 246 cases. According to the results of TCT,the women were classified into normal group,atypical squamous cell of undetermined significance （ASCUS）group,low-grade squamous intraepithelial lesion （LSIL）group and high-grade squamous intraepithelial lesion （HSIL）group. Results The positive rate of HPV DNA determination [17.67%（718/4 062）] was higher than that of HPV E6/E7 mRNA determination [12.12%（151/1 246）] （P<0.05）. The positive rates of HPV DNA determination and HPV E6/ E7 mRNA determination had no statistical significance among HSIL,LSIL and ASCUS groups （P>0.05）. The positive rate of HPV DNA determination in normal group was 15.07%,which was higher than that of HPV E6/E7 mRNA determination （8.90%）（P<0.05）. The positive proportions of HPV DNA and HPV E6/E7 determinations in these groups had no statistical significance （P<0.05）. LSIL and HSIL were determined as cytopathological positive,and normal group and ASCUS group were determined as cytopathological negative. The proportions of LSIL and HSIL in the positive cases of HPV E6/E7 mRNA determination [15.23%（23/151）] were higher than those in HPV DNA determination positive cases [8.64%（62/718）]（P<0.05）. There was no statistical significance for sensitivities of LSIL+HSIL screening between HPV DNA determination （83.78%）and HPV E6/E7 mRNA determination （85.19%）（P>0.05）. The specificities were 83.55% and 89.50%,respectively （P<0.05）. Conclusions HPV E6/E7 mRNA determiantion is suitable for screening HPV infection. It is more specific than HPV DNA determination for screening LSIL and HSIL. It is suitable for clinical cervical cancer screening.

Key words: Human papillomavirus, Thinprep cytologic test, Cervical cancer screening

CLC Number:

R446.1

XUAN Qiankun, GUO Jian, WU Wenjuan, LI Guangbo. Clinical application of human papillomavirus E6/E7 mRNA determination[J]. Laboratory Medicine, 2018, 33(7): 640-643.

Figures/Tables 1

References 14

[1]	TORRE L A,BRAY F,SIEGEL R L, et al.Global cancer statistics,2012[J]. CA Cancer J Clin,2015,65(2):87-108.
[2]	WALBOOMERS J M,JACOBS M V,MANOS M M,et al.Human papillomavirus is a necessary cause of invasive cervical cancer worldwide[J]. J Pathol,1999,189(1):12-19.
[3]	RONCO G,DILLNER J,ELFSTRÖM K M,et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials[J]. Lancet,2014,383(9916):524-532.
[4]	FONTECHA N,BASARAS M,HERNÁEZ S,et al. Assessment of human papillomavirus E6/E7 oncogene expression as cervical disease biomarker[J]. BMC Cancer,2016,16(1):852.
[5]	SASLOW D,SOLOMON D,LAWSON H W,et al.American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer[J]. Am J Clin Pathol,2012,137(4):516-542.
[6]	MOYER V A,U. S. Preventive Services Task Force. Screening for cervical cancer: U. S. Preventive Services Task Force recommendation statement[J]. Ann Intern Med,2012,156(12):880-891.
[7]	SASLOW D,SOLOMON D,LAWSON H W,et al.American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer[J]. CA Cancer J Clin,2012,62(3): 147-172.
[8]	朱蓉,居会祥,王锋,等. 高危型HPV DNA检测应用于体检中的价值探讨[J]. 检验医学, 2014,29(4): 347-349.
[9]	SHAIKH F,SANEHI P,RAWAL R.Molecular screening of compounds to the predicted protein-protein interaction site of Rb1-E7 with p53-E6 in HPV[J]. Bioinformation, 2012,8(13):607-612.
[10]	RAMPIAS T,BOUTATI E,PECTASIDES E,et al.Activation of Wnt signaling pathway by human papillomavirus E6 and E7 oncogenes in HPV16-positive oropharyngeal squamous carcinoma cells[J]. Mol Cancer Res,2010,8(3):433-443.
[11]	DOORBAR J.Molecular biology of human papillomavirus infection and cervical cancer[J]. Clin Sci (Lond), 2006,110(5):525-541.
[12]	NOLTE F S,RIBEIRO-NESBITT D G. Comparison of the Aptima and Cervista tests for detection of high-risk human papillomavirus in cervical cytology specimens[J]. Am J Clin Pathol,2014,142(4): 561-566.
[13]	WRIGHT T C Jr,STOLER M H,SHARMA A,et al. Evaluation of HPV-16 and HPV-18 genotyping for the triage of women with high-risk HPV+ cytology-negative results[J]. Am J Clin Pathol,2011,136(4): 578-586.
[14]	SØRBYE S W,FISMEN S,GUTTEBERG T J,et al. Primary cervical cancer screening with an HPV mRNA test:a prospective cohort study[J]. BMJ Open,2016,6(8):e011981.

组别	例数	HPV DNA		HPV E6/E7 mRNA
组别	例数	检测例数	阳性例数（%）	检测例数	阳性例数（%）
HSIL组	32	23	22（95.65）	9	8（88.89）
LSIL组	69	51	40（78.43）	18	15（83.33）
ASCUS组	231	180	82（45.56）	51	24（47.06）
正常组	4 976	3 808	574（15.07）	1 168	104（8.90）^*
合计	5 308	4 062	718（17.67）	1 246	151（12.12）^*

组别	例数	HPV DNA		HPV E6/E7 mRNA
组别	例数	检测例数	阳性例数（%）	检测例数	阳性例数（%）
HSIL组	32	23	22（95.65）	9	8（88.89）
LSIL组	69	51	40（78.43）	18	15（83.33）
ASCUS组	231	180	82（45.56）	51	24（47.06）
正常组	4 976	3 808	574（15.07）	1 168	104（8.90）^*
合计	5 308	4 062	718（17.67）	1 246	151（12.12）^*

[1]	ZHANG Yaxu, CUI Yanwei, LIU Ziyan. Preliminary research for the determination of HPV E6/E7 mRNA by nucleic acid molecular hybridization-flow cytometry [J]. Laboratory Medicine, 2023, 38(1): 46-50.
[2]	LIU Hongqian, SONG Chaohui, LIANG Qiaomi. Determination and quantitation of blood human papillomavirus DNA in healthy subjects [J]. Laboratory Medicine, 2021, 36(11): 1121-1124.
[3]	XUAN Binbin, TAN Meiyu, SUN Hanxiao, SHENG Huiming. Mixed infection status of human papillomavirus,Ureaplasma urealyticum,Chlamydia trachomatis and Neisseria gonorrhoeae in Changning district of Shanghai [J]. Laboratory Medicine, 2020, 35(9): 859-863.
[4]	HOU Jianghou, ZHANG Lingxia, SUN Wenna, LIU Yanhua, YANG Bingfen, SUN Weiguo. Prokaryotic expression and serological verification of antigenic epitopes of human papillomavirus type 16 L1 protein [J]. Laboratory Medicine, 2020, 35(9): 928-932.
[5]	SHEN Qionghua. Role of HPV DNA typing in the differential diagnosis of cervical lesions and cervical cancer [J]. Laboratory Medicine, 2019, 34(6): 498-501.
[6]	HUANG Yan, ZHU Xiaoyun, LI Tianying. Role of human papillomavirus DNA assay combined with liquid-based cytology for screening cervical lesion [J]. Laboratory Medicine, 2019, 34(4): 313-317.
[7]	CAI Pengfei, XU Zehui, WANG Jingren, YAN Tizhen. Results' analysis of human papillomavirus determination of 9 810 patients in Liuzhou,Guangxi [J]. Laboratory Medicine, 2019, 34(3): 246-248.
[8]	YANG Yang, CHEN Liangyuan, CAO Pengju, CHEN Shaoting, ZHANG Qiuqin, HUANG Chunli, WU Qiumei, CHEN Falin. Analysis of HPV infection and gene subtypes in physical examination women in Fuzhou [J]. Laboratory Medicine, 2019, 34(2): 144-147.
[9]	SUN Yongmei, CHEN Zhaowu, ZHANG Yang, WAN Lingling, LI Ming, DENG Fang. HPV infection status of cervical cancer patients in Anhui and role of HPV determination in monitoring the curative effect of radiotherapy [J]. Laboratory Medicine, 2019, 34(10): 897-900.
[10]	HUANG Luyao, XU Yanyan, LOU Xiaoli, CAO Hui, XIA Wanbao, HOU Yanqiang. Human papillomavirus infection in Shanghai Songjiang [J]. Laboratory Medicine, 2017, 32(8): 695-699.
[11]	YAN Xiaohui, LIN Jinduan. Relationship between human papillomavirus infection and the severity of cervical lesions [J]. Laboratory Medicine, 2017, 32(8): 700-703.
[12]	ZHAO Peiyu, CHEN Aozheng, QIN Jinlong, SONG Liwen, CHENG Jiajing. Cervista HR-HPV DNA testing combined with TCT in cervical cancer screening [J]. Laboratory Medicine, 2017, 32(4): 322-325.
[13]	LI Jun, WANG Yiyu, NAN Xing, WANG Guoqing, LIU Ying, YUAN Rong, YIN Yue, TIAN Xiaofei. Genotyping and subtype distribution of human papillomavirus in Shaanxi Xianyang [J]. Laboratory Medicine, 2017, 32(3): 194-198.
[14]	DING Jing, WANG Quan, WANG Qingguo. High-risk HPV genotyping in cervical lesion samples in Xuzhou [J]. Laboratory Medicine, 2017, 32(3): 199-201.
[15]	ZHANG Xuedan, WENG Yuesong. HPV DNA typing combined with "three-ladder" screening program in the diagnosis of cervical precancerous lesions and prognosis [J]. Laboratory Medicine, 2017, 32(11): 990-993.